 |
| |
| Dec-17-18 | Upgrade |
CL King |
Neutral → Buy |
|
|
| Nov-12-18 | Downgrade |
CL King |
Buy → Neutral |
|
|
| Sep-26-18 | Initiated |
H.C. Wainwright |
Neutral |
$49 |
|
| Dec-08-17 | Initiated |
Citigroup |
Buy |
$45 |
|
| Dec-05-17 | Initiated |
JP Morgan |
Overweight |
$42 |
|
| Nov-13-17 | Initiated |
CL King |
Buy |
|
|
| Oct-02-17 | Upgrade |
First Analysis Sec |
Equal-Weight → Overweight |
$47 |
|
| Jul-21-17 | Initiated |
William Blair |
Outperform |
|
|
| Feb-13-17 | Upgrade |
Piper Jaffray |
Neutral → Overweight |
|
|
| Feb-22-16 | Initiated |
Craig Hallum |
Buy |
|
|
| Nov-06-15 | Downgrade |
Jefferies |
Buy → Hold |
|
|
| Apr-23-15 | Reiterated |
Jefferies |
Buy |
$25 → $38 |
|
| Mar-07-11 | Downgrade |
Rodman & Renshaw |
Mkt Outperform → Mkt Perform |
|
|
| Jun-30-09 | Initiated |
Merriman |
Buy |
|
|
| Jun-12-08 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$11 → $9 |
|
| Sep-10-07 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$6 → $8 |
|
| Apr-12-07 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$5 → $6 |
|
|
|
| Feb-15-19 07:30AM | Repligen to Report Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire |
| Jan-30-19 11:48AM | Is Repligen Corporations (NASDAQ:RGEN) Liquidity Good Enough? Simply Wall St. |
| Jan-28-19 08:00AM | Today's Research Reports on Trending Tickers: Incyte and Repligen ACCESSWIRE -5.14% |
| Jan-25-19 12:21PM | 3 Pick-and-Shovel Biotechnology Stocks Motley Fool |
| Jan-24-19 06:40PM | How to Play It Safe in Biotech Motley Fool |
| Jan-23-19 07:35AM | Consolidated Research: 2019 Summary Expectations for Post, Westlake Chemical, Repligen, Weingarten Realty Investors, AptarGroup, and At Home Group Fundamental Analysis, Key Performance Indications GlobeNewswire |
| Jan-10-19 05:00AM | Top Picks 2019- Repligen RGEN MoneyShow |
| Jan-03-19 01:26PM | Repligen to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire |
| Dec-23-18 04:27AM | Is Repligen Corporation (RGEN) A Good Stock To Buy? Insider Monkey |
| Dec-20-18 12:00PM | Have Insiders Been Selling Repligen Corporation (NASDAQ:RGEN) Shares This Year? Simply Wall St. |
| Dec-17-18 09:30AM | ANIK vs. RGEN: Which Stock Should Value Investors Buy Now? Zacks -5.39% |
| Nov-20-18 11:57AM | Based On Its ROE, Is Repligen Corporation (NASDAQ:RGEN) A High Quality Stock? Simply Wall St. |
| Nov-16-18 02:15PM | Trump Trade Comments Boost Dow Jones; These 6 Growth Stocks Take Market Helm Investor's Business Daily |
| Nov-12-18 08:15AM | Research Report Identifies Prudential Financial, Second Sight Medical Products, Acushnet, Repligen, Scorpio Tankers, and Aethlon Medical with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire |
| Nov-11-18 11:25AM | Edited Transcript of RGEN earnings conference call or presentation 1-Nov-18 12:30pm GMT Thomson Reuters StreetEvents |
| Nov-09-18 01:25PM | Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018 Investor's Business Daily |
| Nov-04-18 06:49PM | 3 Growth Stocks for In-the-Know Investors Motley Fool |
| Nov-02-18 08:01AM | The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug Benzinga |
| Nov-01-18 04:19PM | IBD Stock Of The Day Breaks Out On Strong Quarterly Report, Outlook Investor's Business Daily +17.21% |
| 12:22PM | Here's Why Repligen Rose More Than 16% Today Motley Fool |
| 08:09AM | Repligen: 3Q Earnings Snapshot Associated Press |
| 07:30AM | Repligen Reports Third Quarter 2018 Financial Results GlobeNewswire |
| Oct-22-18 07:30AM | Repligen to Report Third Quarter 2018 Financial Results GlobeNewswire |
| Oct-17-18 08:25AM | Recent Analysis Shows Repligen, SpartanNash, AZUL SA, Pacira Pharmaceuticals, Ichor, and Scorpio Tankers Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
| Oct-05-18 08:49AM | Repligen Corporation (NASDAQ:RGEN): Earnings To Drop Next Year Simply Wall St. |
| Aug-22-18 08:15AM | Recent Analysis Shows STMicroelectronics N.V, Jagged Peak Energy, Inovalon, AC Immune SA, Repligen, and RealNetworks Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
| Aug-03-18 09:19PM | Edited Transcript of RGEN earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents |
| Aug-02-18 12:55PM | Repligen (RGEN) Misses Q2 Earnings Estimates Zacks |
| 11:49AM | Repligen: 2Q Earnings Snapshot Associated Press |
| 07:30AM | Repligen Reports Second Quarter 2018 Financial Results GlobeNewswire |
| 06:30AM | Repligen Corporation to Host Earnings Call ACCESSWIRE |
| Aug-01-18 08:00AM | Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Repligen ACCESSWIRE |
| Jul-19-18 11:48AM | Repligen to Report Second Quarter 2018 Financial Results GlobeNewswire |
| Jun-28-18 07:35AM | Purolite Life Sciences Announces the Launch of Praesto® Jetted A50 Using Proprietary Jetting Technology - Leading the Future of Protein A Chromatography Resins PR Newswire |
| 07:30AM | Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand GlobeNewswire |
| Jun-27-18 07:30AM | Repligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity Ligands GlobeNewswire |
| Jun-19-18 01:25PM | CVS will offer home delivery of prescriptions Yahoo Finance Video |
| Jun-11-18 07:50AM | Report: Exploring Fundamental Drivers Behind Matthews International, Raytheon, JetBlue Airways, Repligen, Becton, Dickinson, and Macy's New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
| May-30-18 07:30AM | Repligen to Present at the William Blair 2018 Growth Stock Conference GlobeNewswire |
| May-23-18 07:34AM | Moving Average Crossover Alert: Repligen (RGEN) Zacks |
| 07:30AM | Repligen to Present at Jefferies 2018 Global Healthcare Conference GlobeNewswire |
| May-17-18 07:30AM | Repligen to Participate in 15th Annual Craig-Hallum Institutional Investor Conference GlobeNewswire |
| May-10-18 07:46AM | Edited Transcript of RGEN earnings conference call or presentation 8-May-18 12:30pm GMT Thomson Reuters StreetEvents |
| May-08-18 07:59AM | Repligen: 1Q Earnings Snapshot Associated Press +5.66% |
| 07:30AM | Repligen Reports First Quarter 2018 Financial Results GlobeNewswire |
| May-01-18 09:52AM | Biotechnology Movers: Karyopharm Therapeutics Inc. and Regeneron Pharmaceuticals Market Exclusive |
| 07:35AM | Analysis: Positioning to Benefit within USA Compression Partners, LP, Kadmon, Repligen, Independent Bank, Leggett & Platt, and Esterline Technologies Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire |
| Apr-30-18 11:00AM | Repligen to Report First Quarter 2018 Financial Results GlobeNewswire |
| Apr-26-18 10:50AM | 3 Top Growth Stocks to Buy Right Now Motley Fool |
| Apr-24-18 07:47AM | 3 Top Stocks You Can Buy and Hold for the Next Decade Motley Fool |
| Apr-12-18 06:33AM | My Investing Horror Story: Selling Too Early Motley Fool |
| Apr-03-18 04:55PM | Should You Be Tempted To Sell Repligen Corporation (NASDAQ:RGEN) Because Of Its PE Ratio? Simply Wall St. |
| Mar-26-18 06:48PM | Repligen Corporation (NASDAQ:RGEN): Is It A Good Long Term Opportunity? Simply Wall St. |
| Mar-20-18 07:30AM | Repligen Announces Market Launch of OPUS® 80R, Reinforces Technology Leadership in Pre-Packed Chromatography GlobeNewswire |
| 07:30AM | Analysis: Positioning to Benefit within Clearwater Paper, Energous, MINDBODY, Agilysys, Repligen, and Unit Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire |
| Mar-16-18 04:38PM | Will Repligen Corporations (NASDAQ:RGEN) Earnings Grow In The Year Ahead? Simply Wall St. |
| Feb-23-18 03:02AM | Edited Transcript of RGEN earnings conference call or presentation 22-Feb-18 1:30pm GMT Thomson Reuters StreetEvents |
| Feb-22-18 08:43AM | Repligen beats Street 4Q forecasts Associated Press +7.96% |
| 07:30AM | Repligen Reports Fourth Quarter 2017 Financial Results, Provides Guidance for 2018 GlobeNewswire |
| 06:40AM | Repligen Corporation to Host Earnings Call ACCESSWIRE |
| Feb-16-18 07:30AM | Repligen to Report Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire |
| Jan-17-18 07:50AM | Report: Developing Opportunities within Repligen, Avid Technology, Reata Pharmaceuticals, Stellus Capital Investment, American Financial Group, and Actuant Future Expectations, Projections Moving into 2018 GlobeNewswire |
| Jan-02-18 08:04AM | See what the IHS Markit Score report has to say about Repligen Corp. Markit |
| Dec-29-17 01:47PM | Repligen To Present at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire |
| 12:28PM | ETFs with exposure to Repligen Corp. : December 29, 2017 Capital Cube |
| Dec-28-17 09:23AM | Repligen Corp. :RGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017 Capital Cube |
| Dec-20-17 06:34AM | 3 Growth Stocks to Buy for 2018 Motley Fool |
| Dec-19-17 02:45PM | Repligen Corp. Value Analysis (NASDAQ:RGEN) : December 19, 2017 Capital Cube |
| Dec-18-17 08:03AM | Repligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : December 18, 2017 Capital Cube |
| Dec-13-17 06:54PM | Why Repligen Corporations (NASDAQ:RGEN) ROE Of 5.70% Does Not Tell The Whole Story Simply Wall St. |
| Dec-10-17 03:59PM | Top 3 Healthcare Penny Stocks for 2017 Investopedia |
| Dec-07-17 09:00AM | 3 Growth Stocks to Buy and Hold for 25 Years Motley Fool |
| Nov-29-17 09:16AM | 3 Bioeconomy Stocks That Have a Killer Advantage Motley Fool |
| Nov-28-17 08:03AM | See what the IHS Markit Score report has to say about Repligen Corp. Markit |
| Nov-16-17 07:20AM | Featured Company News - TapImmune Announced Final Patient Enrollment Ahead of Schedule in Phase-2 Cancer Vaccine Study For TNBC ACCESSWIRE |
| Nov-15-17 08:08AM | See what the IHS Markit Score report has to say about Repligen Corp. Markit |
| Nov-13-17 03:38AM | Edited Transcript of RGEN earnings conference call or presentation 9-Nov-17 1:30pm GMT Thomson Reuters StreetEvents |
| Nov-09-17 08:04AM | See what the IHS Markit Score report has to say about Repligen Corp. Markit |
| 07:43AM | Repligen tops Street 3Q forecasts Associated Press |
| 07:30AM | Repligen Reports Third Quarter 2017 Financial Results GlobeNewswire |
| 07:00AM | Repligen Corporation to Host Earnings Call ACCESSWIRE |
| Nov-08-17 12:20PM | Top 3 Healthcare Penny Stocks for 2017 Investopedia |
| 08:58AM | Should You Sell Repligen Corporation (RGEN) Before Earnings? Zacks |
| Nov-07-17 11:07AM | 5 Biotech Stocks Well Poised to Surpass Expectations in Q3 Zacks |
| 07:30AM | Repligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands GlobeNewswire |
| Nov-06-17 08:04AM | See what the IHS Markit Score report has to say about Repligen Corp. Markit |
| Nov-01-17 12:36PM | ETFs with exposure to Repligen Corp. : November 1, 2017 Capital Cube |
| 11:14AM | Repligen to Report Third Quarter 2017 Financial Results GlobeNewswire |
| 07:58AM | Purolite Selects Repligen's Market-Leading OPUS® Pre-Packed Columns PR Newswire |
| Oct-31-17 03:00AM | Stocks With Rising Relative Strength: Repligen Investor's Business Daily |
| Oct-26-17 08:02AM | See what the IHS Markit Score report has to say about Repligen Corp. Markit |
| Oct-20-17 10:24AM | ETFs with exposure to Repligen Corp. : October 20, 2017 Capital Cube |
| Oct-17-17 08:02AM | See what the IHS Markit Score report has to say about Repligen Corp. Markit -5.16% |
| Oct-16-17 09:41AM | See what the IHS Markit Score report has to say about Repligen Corp. Markit |
| Oct-09-17 11:59AM | ETFs with exposure to Repligen Corp. : October 9, 2017 Capital Cube |
| Oct-02-17 08:03AM | See what the IHS Markit Score report has to say about Repligen Corp. Markit |
| Sep-28-17 10:19AM | ETFs with exposure to Repligen Corp. : September 28, 2017 Capital Cube |
| Sep-27-17 09:04AM | Repligen Corp. :RGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017 Capital Cube |
| 08:18AM | Repligen Corp. breached its 50 day moving average in a Bearish Manner : RGEN-US : September 27, 2017 Capital Cube |
| Sep-15-17 07:30AM | Repligen Announces Analyst Day and Webcast GlobeNewswire |
|
|
|
|
| Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company has a collaboration agreement with Navigo Proteins GmbH for the advancement of affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| KURIYEL RALF | Senior VP, R&D | Dec 18 | Sale | 54.44 | 311 | 16,931 | 12,294 | Dec 20 04:22 PM | | Snodgres Jon | CFO | Nov 26 | Option Exercise | 27.12 | 31,753 | 861,132 | 52,652 | Nov 28 04:43 PM | | Snodgres Jon | CFO | Nov 26 | Sale | 63.49 | 31,753 | 2,015,915 | 20,899 | Nov 28 04:43 PM | | RYAN THOMAS F JR | Director | Nov 05 | Sale | 65.75 | 1,763 | 115,920 | 3,225 | Nov 06 06:29 PM | | Hunt Anthony | Chief Executive Officer | Sep 10 | Option Exercise | 16.55 | 11,873 | 196,498 | 255,017 | Sep 12 04:15 PM | | Hunt Anthony | Chief Executive Officer | Sep 10 | Sale | 57.71 | 27,566 | 1,590,809 | 227,451 | Sep 12 04:15 PM | | BARTHELEMY NICOLAS | Director | Aug 29 | Option Exercise | 39.85 | 4,426 | 176,392 | 10,766 | Aug 31 04:15 PM | | BARTHELEMY NICOLAS | Director | Aug 29 | Sale | 54.44 | 6,580 | 358,196 | 4,186 | Aug 31 04:15 PM | | Snodgres Jon | CFO | Aug 28 | Sale | 52.79 | 14,460 | 763,359 | 20,899 | Aug 29 04:15 PM | | RYAN THOMAS F JR | Director | Aug 22 | Sale | 51.44 | 2,366 | 121,698 | 4,988 | Aug 24 04:16 PM | | EDDLEMAN ROY T | 10% Owner | Aug 09 | Sale | 49.63 | 116,073 | 5,760,536 | 370,000 | Aug 13 04:06 PM | | EDDLEMAN ROY T | 10% Owner | Aug 08 | Sale | 49.05 | 4,770 | 233,970 | 409,215 | Aug 08 06:10 PM | | EDDLEMAN ROY T | 10% Owner | Aug 07 | Sale | 49.05 | 16,015 | 785,577 | 413,985 | Aug 08 06:10 PM | | EDDLEMAN ROY T | 10% Owner | Aug 06 | Sale | 49.05 | 33,142 | 1,625,599 | 796,858 | Aug 08 06:10 PM | | RYAN THOMAS F JR | Director | Jun 06 | Sale | 44.31 | 1,932 | 85,606 | 7,354 | Jun 07 04:28 PM | | Hunt Anthony | Chief Executive Officer | May 21 | Sale | 42.53 | 16,249 | 691,016 | 243,144 | May 22 05:12 PM | | EDDLEMAN ROY T | 10% Owner | May 16 | Sale | 42.07 | 118,850 | 5,000,020 | 2,925,976 | May 18 10:46 AM | | DAWES KAREN A | Director | May 11 | Option Exercise | 5.08 | 20,000 | 101,600 | 114,957 | May 15 09:53 AM | | DAWES KAREN A | Director | May 11 | Sale | 41.80 | 20,000 | 835,936 | 94,957 | May 15 09:53 AM | | BARTHELEMY NICOLAS | Director | May 09 | Option Exercise | 21.08 | 27,366 | 576,800 | 31,354 | May 11 10:38 AM | | EDDLEMAN ROY T | 10% Owner | May 09 | Sale | 40.44 | 45,773 | 1,850,972 | 410,000 | May 09 06:59 PM | | BARTHELEMY NICOLAS | Director | May 09 | Sale | 40.54 | 26,500 | 1,074,238 | 4,854 | May 11 10:38 AM | | EDDLEMAN ROY T | 10% Owner | May 08 | Sale | 40.73 | 74,227 | 3,023,485 | 430,773 | May 09 06:59 PM | | RYAN THOMAS F JR | Director | Mar 08 | Option Exercise | 14.95 | 4,696 | 70,192 | 13,396 | Mar 12 05:32 PM | | RYAN THOMAS F JR | Director | Mar 08 | Sale | 36.16 | 4,696 | 169,792 | 8,700 | Mar 12 05:32 PM |
|
|
|
|
|
|
